Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

Open access
Watkins, Benjamin, Qayed, Muna, McCracken, Courtney, Bratrude, Brandi, Betz, Kayla, Suessmuth, Yvonne, Yu, Alison, Sinclair, Shauna, Furlan, Scott, Bosinger, Steven, Tkachev, Victor, Rhodes, James, Tumlin, Audrey Grizzle, Narayan, Alexandria, Cribbin, Kayla, Gillespie, Scott, Gooley, Ted A., Pasquini, Marcelo C., Hebert, Kyle, Kapoor, Urvi, Rogatko, Andre, Tighiouart, Mourad, Kim, Sungjin, Bresee, Catherine, Choi, Sung W., Davis, Jeffrey, Duncan, Christine, Giller, Roger, Grimley, Michael, Harris, Andrew C., Jacobsohn, David, Lalefar, Nahal, Norkin, Maxim, Farhadfar, Nosha, Pulsipher, Michael A., Shenoy, Shalini, Petrovic, Aleksandra, Schultz, Kirk R., Yanik, Gregory A., Waller, Edmund K., Levine, John E., Ferrara, James L., Blazar, Bruce R., Langston, Amelia, Horan, John T., Kean, Leslie S.·2021·Journal of Clinical Oncology

Abstract

PURPOSE: Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need for novel therapeutics. ABA2 was a phase II trial to rigorously assess safety, efficacy, and immunologic effects of adding T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)-based GVHD prophylaxis, to test whether abatacept could decrease AGVHD. METHODS: ABA2 enrolled adults and children with hematologic malignancies under two strata: a randomized, double-blind, placebo-controlled stratum (8/8-HLA-matched URD), comparing CNI/MTX plus abatacept with CNI/MTX plus placebo, and a single-arm stratum (7/8-HLA-mismatched URD) comparing CNI/MTX plus abatacept versus CNI/MTX CIBMTR controls. The primary end point was day +100 grade 3-4 AGVHD, with day +180 severe-AGVHD-free-survival (SGFS) a key secondary end point. Sample sizes were calculated using a higher type-1 error (0.2) as recommended for phase II trials, and were based on predicting that abatacept would reduce grade 3-4 AGVHD from 20% to 10% (8/8s) and 30% to 10% (7/8s). ABA2 enrolled 142 recipients (8/8s, median follow-up = 716 days) and 43 recipients (7/8s, median follow-up = 708 days). RESULTS: In 8/8s, grade 3-4 AGVHD was 6.8% (abatacept) versus 14.8% (placebo) ( P = .13, hazard ratio = 0.45). SGFS was 93.2% (CNI/MTX plus abatacept) versus 82% (CNI/MTX plus placebo, P = .05). In the smaller 7/8 cohort, grade 3-4 AGVHD was 2.3% (CNI/MTX plus abatacept, intention-to-treat population), which compared favorably with a nonrandomized matched cohort of CNI/MTX (30.2%, P < .001), and the SGFS was better (97.7% v 58.7%, P < .001). Immunologic analysis revealed control of T-cell activation in abatacept-treated patients. CONCLUSION: Adding abatacept to URD HCT was safe, reduced AGVHD, and improved SGFS. These results suggest that abatacept may substantially improve AGVHD-related transplant outcomes, with a particularly beneficial impact on HLA-mismatched HCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.01086

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 264

Metadata

Authors
Watkins, B., Qayed, M., McCracken, C., Bratrude, B., Betz, K., Suessmuth, Y., Yu, A., Sinclair, S., Furlan, S., Bosinger, S., Tkachev, V., Rhodes, J., Tumlin, A. G., Narayan, A., Cribbin, K., Gillespie, S., Gooley, T. A., Pasquini, M. C., Hebert, K., Kapoor, U., Rogatko, A., Tighiouart, M., Kim, S., Bresee, C., Choi, S. W., Davis, J., Duncan, C., Giller, R., Grimley, M., Harris, A. C., Jacobsohn, D., Lalefar, N., Norkin, M., Farhadfar, N., Pulsipher, M. A., Shenoy, S., Petrovic, A., Schultz, K. R., Yanik, G. A., Waller, E. K., Levine, J. E., Ferrara, J. L., Blazar, B. R., Langston, A., Horan, J. T., & Kean, L. S.
Venue
Journal of Clinical Oncology
Published
2021-06-10
Volume
39
Issue
17
Pages
1865-1877
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3120895755
Cited by
264
References
25
FWCI
23.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. https://app.cochat.ai/papers/10.1200/jco.20.01086
The paper
Watkins, B., Qayed, M., McCracken, C., Bratrude, B., Betz, K., Suessmuth, Y., Yu, A., Sinclair, S., Furlan, S., Bosinger, S., Tkachev, V., Rhodes, J., Tumlin, A. G., Narayan, A., Cribbin, K., Gillespie, S., Gooley, T. A., Pasquini, M. C., Hebert, K., . . . Kean, L. S. (2021). Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.01086

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.